Free tool
FAERS Monitor: Foscavir
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020068 or its brand name (Foscavir, Foscarnet Sodium). Reports on generic versions are filed under their own applications.
Reports
1,935
Serious
1,894
98% of reports
Hospitalization
785
Death reported
702
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use502
- drug ineffective209
- acute kidney injury197
- pancytopenia190
- cytomegalovirus infection182
- drug resistance145
- renal impairment124
- pyrexia111
- nephropathy toxic109
- cystitis haemorrhagic100
- encephalitis cytomegalovirus99
- cytomegalovirus infection reactivation97
- renal failure92
- cytomegalovirus viraemia91
- myelosuppression91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 22 |
| 2006 | 25 |
| 2007 | 21 |
| 2008 | 53 |
| 2009 | 45 |
| 2010 | 35 |
| 2011 | 79 |
| 2012 | 67 |
| 2013 | 71 |
| 2014 | 60 |
| 2015 | 47 |
| 2016 | 110 |
| 2017 | 158 |
| 2018 | 149 |
| 2019 | 183 |
| 2020 | 159 |
| 2021 | 112 |
| 2022 | 98 |
| 2023 | 89 |
| 2024 | 134 |
| 2025 | 138 |
| 2026 | 61 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,224 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| encephalitis cytomegalovirusSignal | 99 | 3177.3 | 2551.3 | 240,851 |
| cystitis haemorrhagicSignal | 100 | 276.5 | 227.9 | 26,506 |
| cytomegalovirus infection reactivationSignal | 97 | 244.0 | 200.5 | 22,728 |
| cytomegalovirus viraemiaSignal | 91 | 227.0 | 185.3 | 19,838 |
| cytomegalovirus infectionSignal | 182 | 120.3 | 104.7 | 21,202 |
| nephropathy toxicSignal | 109 | 106.6 | 88.7 | 11,190 |
| drug resistanceSignal | 145 | 61.7 | 52.7 | 8,560 |
| pancytopeniaSignal | 190 | 37.1 | 32.4 | 6,629 |
| myelosuppressionSignal | 91 | 27.5 | 22.5 | 2,298 |
| renal impairmentSignal | 124 | 16.1 | 13.5 | 1,741 |
| acute kidney injurySignal | 197 | 14.0 | 12.3 | 2,381 |
| renal failureSignal | 92 | 7.5 | 6.2 | 518 |
| off label useSignal | 502 | 6.2 | 5.8 | 2,295 |
| pyrexiaSignal | 111 | 3.5 | 2.9 | 198 |
| drug ineffective | 209 | 1.7 | 1.5 | 67 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.